Imalux Differentiates Grades of Cervical Dysplasia
Cleveland, OH--Imalux Corporation's Imalux’s Niris® Imaging System differentiated grades of pre-invasive cervical dysplasia with statisticals significance, prior to biopsy, in two studies of over 2,000 patients. The studies, conducted in China by Imalux and Preventive Oncology International, Inc., in partnership with the Peking Shenzhen Hospital and Renmin Hospital in Buyi-Miao Autonomous District of Guizhou Provice, compared 2,800 Niris® images with clinician's diagnostic impressions and pathology findings.
"These studies showed that we could use Imalux’s Niris® Imaging System in both high- and low-resource settings with the intent to improve women’s health care globally,”said Dr. Nancy Tresser, VP and Chief Medical Officer of Imalux. Epidemiologist Dr. Suzanne Belinson (POI) will be presenting the statistical results of the study at the 25th International Papillomavirus Conference in Malmo, Sweden this May. Her conclusions are based on the analysis of differences in the brightness of cervical epithelium images. She found that the mean brightness differed significantly between each histological grade (p-values 0.000) for the comparisons of two grades of precancerous dysplasia (CIN II, CIN III) and their comparisons to cancer, as well as squamous metaplasia to cancer. Read more...
Find Out More About ESP
Early Stage Partners Managing Director Jonathan Murray sits on the Imaux board.